GSK is on the brink of EU approval for JAK inhibitor momelotinib as a treatment for myelofibrosis patients with anaemia, after the EMA’s human medicines committee issued a
GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquire
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl